Skip to main content
Jennifer L. Pauley, BS, PharmD, BCPS, BCOP

Jennifer L. Pauley, BS, PharmD, BCPS, BCOP

  • Clinical Coordinator
  • Director, ASHP-Accredited PGY2 Oncology Residency (Pediatric Focus)
  • Assistant Professor, The University of Tennessee Health Sciences Center, Department of Clinical Pharmacy and Translational Science

Departments

Board Certification(s)

  • BCPS
  • BCOP

Education

BS – The Ohio State University, Columbus, Ohio
PharmD - The Ohio State University, Columbus, Ohio
Residency – Pediatric Pharmacotherapy, Texas Children’s Hospital

Focused Area of Practice

  • Leukemia/Lymphoma
  • Residency Training

Honors & Awards

  • 2020  Clinical Care Improvement Award for Clinical Pharmacy Services, St. Jude Children’s Research Hospital
  • 2016  Clinical Care Improvement Award for Antimicrobial Stewardship Program, St. Jude Children’s Research Hosptial 2016 

Research Interests

  • Global Pharmaceutical Care
  • Leukemia/Lymphoma
  • Residency Training
  • Preceptor Development

St. Jude Committee Service

  • Antimicrobial Utilization and Improvement
  • Continuing Medical Education
  • Graduate Medical Education Committee
  • Medication-Use Safety Team
  • Pharmaceutical Department Residency Committee
  • Pharmaceutical Department Residency Directors’ Committee

Pharmacy Organizations/Committee Service

  • American College of Clinical Pharmacy
  • American Society of Health-System Pharmacists 
  • Children’s Oncology Group 
  • Hematology/Oncology Pharmacy Association 
  • MidSouth College of Clinical Pharmacy 
  • Pediatric Pharmacy Association
  • Tennessee Pharmacists Association 

Selected Publications

Quinn M, Fannin JT, Sciasci J, Bragg A, Campbell PK, Carias D, Crews KR, Gregornik D, Jeha S, Maron G, Pauley JL, et al. Pentamidine for prophylaxis against pneumocystis jirovecii pneumonia in pediatric oncology patients receiving immunosuppressive chemotherapy. Antimicrob Agents Chemother. 2018 Jul 27;62(8).

Ramsey LB, Balis FM, O’Brien MM, Schmeigelow K, Pauley JL, et al. Consensus guidelines for the use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury an delayed methotrexate excretion. Oncologist. 2018 Jan;23(1):52-61.

Millisor VE, Roberts JK, Sun Y, Tang L, Daryani VM, Gregornik D, Cross, SJ, Ward D, Pauley JL, et al. Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patients. Pediatr Nephrol. 2017 Sep;32(9):1575-84.

Watts CS, Sciasci JN, Pauley JL, Panetta JC, et al. Prophylactic trimethoprim-sulfamethoxazole does not affect pharmacokinetics or pharmacodynamics of methotrexate. J Pediatr Hematol Oncol. 2016 Aug;38(6):449-52.

Pauley JL, Panetta JC, Crews KR, et al. Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cancer Chemother Pharmacol. 2013 Aug;72(2):369-78.

Bernardo VA, Cross SJ, Crews KR, Flynn PM, Hoffman JM, Knapp KM, Pauley JL, et al.  Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer.  Ann Pharmacother. 2013 Jul;47(7-8):976-83.

Buaboonnam J, Cao X, Pauley JL, Pui CH, et al. Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2013 Jul;60(7):1161-4.

Christensen AM, Pauley JL, Molinelli AR, et al. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer. 2012 Sep 1;118(17):4321-30.

Inaba H, Bhojwani D, Pauley JL, et al. Combination chemotherapy with clofarabine, cyclophosphamide and etoposide in children with refractory or relapsed haematological malignancies. Br J Haematol. 2011 Aug 25.

Anghelescu DL, Faughnan LG, Jeha S, Relling MV, Hinds PS, Sandlund JT, Cheng C, Pei D, Hankins G, Pauley JL, Pui CH. Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer, 2011 Dec 15;57(7):1147-53.

Crews KR, Zhou Y, Pauley JL, Howard SC, Jeha S, Relling MV, Pui CH. Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia. Cancer, 2010 Jan 1;116(1):227-32.

Brugnoletti F, Morris EB, Laningham FH, Patay Z, Pauley JL, Pui CH, Jeha S, Inaba H.  Recurrent intrathecal Methotrexate induced neurotoxicity in an adolescent with acute lymphoblastic leukemia: Serial clinical and radiologic findings. Pediatr Blood Cancer, 2009 52(2):293-5.

Pauley JL, Panetta JC, et al.  Late-Onset Delayed Excretion of Methotrexate.  Cancer Chemother Pharmacol, 2004(54):146-152.

Last update: October 2020